Coding Long COVID: Characterizing a new disease through an ICD-10 lens

Emily R Pfaff,Charisse Madlock-Brown,John M. Baratta,Abhishek Bhatia,Hannah Davis,Andrew Girvin,Elaine Hill,Liz Kelly,Kristin Kostka,Johanna Loomba,Julie A. McMurry,Rachel Wong,Tellen D Bennett,Richard Moffitt,Christopher G Chute,Melissa Haendel,,

DOI: https://doi.org/10.1101/2022.04.18.22273968

2022-04-19

Abstract:Abstract Naming a newly discovered disease is always challenging; in the context of the COVID-19 pandemic and the existence of post-acute sequelae of SARS-CoV-2 infection (PASC), which includes Long COVID, it has proven especially challenging. Disease definitions and assignment of a diagnosis code are often asynchronous and iterative. The clinical definition and our understanding of the underlying mechanisms of Long COVID are still in flux. The deployment of an ICD-10-CM code for Long COVID in the US took nearly two years after patients had begun to describe their condition. Here we leverage the largest publicly available HIPAA-limited dataset about patients with COVID-19 in the US to examine the heterogeneity of adoption and use of U09.9, the ICD-10-CM code for “Post COVID-19 condition, unspecified.” Our results include a characterization of common diagnostics, treatment-oriented procedures, and medications associated with U09.9-coded patients, which give us insight into current practice patterns around Long COVID. We also established the diagnoses most commonly co-occurring with U09.9, and algorithmically clustered them into three major categories: cardiopulmonary, neurological, and metabolic. We aim to apply the patterns gleaned from this analysis to flag probable Long COVID cases occurring prior to the existence of U09.9, thus establishing a mechanism to ensure patients with earlier cases of Long-COVID are no less ascertainable for current and future research and treatment opportunities.